Chapter 17

Neurosurgical Implications of Avastin

Gazanfar Rahmathulla and Michael A. Vogelbaum

Abstract

<p>Malignant gliomas are optimally managed with maximal surgical resection followed by radiation and chemotherapy. Drug delivery challenges and chemoresistance limits the efficacy of standard chemotherapeutic agents. Understanding glioma biology has led to the development of a variety newer molecular targeting agents which have begun to show exciting preliminary results. Bevacizumab (Avastin) is one such drug likely to play a key role in malignant glioma therapy. We review the current literature in regard to the use of bevacizumab and its adverse effects in neurosurgical patients.</p>

Total Pages: 107-110 (4)

Purchase Chapter  Book Details

RELATED BOOKS

.Topics in Anti-Cancer Research.
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.
.The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo.
.Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers.